|Awarded On||August 18, 2021|
|Title||Leveraging glioma stem cell electrophysiology for therapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Robert Rostomily|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
The most common adult brain cancer, glioblastoma (GBM) is incurable. Average survivals of 16-20 months have not improved significantly in decades underscoring the need for new approaches to therapy. The GBM stem cell (GSC) is a unique cell type within GBMs that is inherently resistant to treatments. In addition, heterogeneous mutations drive selection for treatment resistant GSC sub-populations within a tumor that drive progression. Here we propose a new strategy targeting GSCs based on leveraging their generic properties essential for maintaining their “identity” and malignant behavior. One such property, with great therapeutic potential, is the GSC cell membrane voltage potential, or ...